by TractManager | Sep 10, 2015 | Health Technology Assessment
Purpose of Technology The second-wave direct-acting antivirals (DAAs) are prescribed to treat chronic hepatitis C with the objective of achieving sustained viral response and preventing harmful liver damage. These agents were developed to address the issues associated...
by TractManager | Sep 8, 2015 | Emerging Technology Report
An injectable synthetic graft substitute proposed as an alternative to autologous bone graft in hindfoot and/or ankle fusion procedures in adults.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Sep 3, 2015 | Emerging Technology Report
Praluent is a member of a new class of lipid-lowering agents known as PCSK9 inhibitors. It is self-administered as a subcutaneous injection in a single-use pre-filled pen or pre-filled syringe. It is indicated for use as an adjunct to diet and maximally tolerated...
by TractManager | Sep 3, 2015 | Health Technology Assessment
Purpose of Technology Low-intensity pulsed ultrasound (US) bone growth stimulators apply low-intensity, pulsed, high-frequency acoustic pressure waves to a fracture site to stimulate bone growth and promote fracture healing. Bone growth stimulators have been developed...
by TractManager | Sep 3, 2015 | Health Technology Assessment
Purpose of Technology Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are monoclonal antibodies that target and inactivate the PCSK9 protein in the liver. This drug is intended to reduce the amount of harmful low-density lipoprotein cholesterol...
Recent Comments